Efficacy of PreOperative Bevacizumab for Diabetic Eye Disease
- Sponsor
- Cairo University
- Study ID
- NCT01041690
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 9 Years - 40 Years
- Healthy Volunteers
- Not accepted
Interventions
- Bevacizumab — DRUG
Study Details
Reports of the use of intravitreal bevacizumab (Avastin, Genentech) for the reduction of neovascularization in proliferative diabetic retinopathy have demonstrated significant regression in the number of new vessels. Reducing the vascularity of neovascular fibrovascular tissue can potentially reduce bleeding intraoperatively and thus facilitate the vitrectomy procedure. The investigators chose to investigate the potential benefit of the use of preoperative bevacizumab in the management of these most complex cases.
Key Dates
- First listed
- Jan 1, 2010
- Start date
- Jun 30, 2007
- Status verified
- Jan 2007
- Primary completion
- Jun 30, 2008
- Completion
- Jun 30, 2008
Study Design
- Enrollment
- 19 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Bevacizumab
Primary Outcome Measure
Intra- and post-operative bleedings were recorded. [ Time Frame: 3 months ]